FINLAY-FR-1 / Finlay Vaccine Institute - LARVOL DELTA

Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens. (PubMed, Front Bioeng Biotechnol) - "These antigens are featured in various COVID-19 vaccine formats, including SOBERANA 01 and the licensed SOBERANA 02, and SOBERANA Plus. We have determined that both the monomeric and dimeric RBD antigens possess the necessary quality attributes for vaccine production. By enabling the customizable production of both RBD forms, this unified manufacturing process provides the required flexibility to adapt rapidly to the ever-changing demands of emerging SARS-CoV-2 variants and different COVID-19 vaccine platforms."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles. (PubMed, RSC Chem Biol) - "Sera of people vaccinated with this vaccine candidate, named Soberana01, show a high inhibition level of the RBD-ACE2 interaction using RBD mutants corresponding to SARS-CoV-2 variants of concern and wild-type expressed using the phage display technology. To our knowledge, this is the first time that the immunostimulation effect of N. meningitidis OMVs is evaluated in vaccine candidates against SARS-CoV-2."

Journal • Infectious Disease • Meningococcal Infections • Novel Coronavirus Disease • Respiratory Diseases

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity. (PubMed, Vaccine) - "Vaccine candidates were safe and immunogenic, and induced live-virus neutralizing antibodies against SARS-CoV-2. The highest values were obtained when outer membrane vesicles were used as adjuvant."

Clinical • Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Por otra parte recuerdo la celeridad con que se publicaron los resultados de inmunogenicidad de la Soberana01 cuando era un requisito validar estudios sobre candidatos vacunales para recibir el apoyo para su desarrollo." (@AdEsRe93)